Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients.

ABSTRACT:

Purpose

The aim of this study was to evaluate whether pretreatment analysis of selected molecular markers can be used for the prediction of disease-free survival (DFS)/overall survival (OS) of capecitabine adjuvant monotherapy in colon cancer patients.

Patients and methods

A total of 126 patients enrolled in a capecitabine Phase IV clinical trial were analyzed for microsatellite instability (MSI), 18q loss of heterozygosity (LOH), thymidylate synthase (TYMS) 5' variable number of tandem repeat (VNTR), and methylene tetrahydrofolate reductase (MTHFR) C677T variants. The significance in predicting 5-year DFS/OS was assessed by Kaplan-Meier and Cox regression analyses.

Results

The MSI-high (MSI-H) genotype was significantly associated with DFS (HR 0.205, 95% CI 0.05-0.88

SUBMITTER: Matevska-Geshkovska N 

PROVIDER: S-EPMC6219100 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature